Tudor Investment Corp’s Neogen NEOG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.19M Sell
235,741
-303,585
-56% -$2.99M ﹤0.01% 1779
2025
Q4
$3.77M Buy
539,326
+528,545
+4,903% +$3.32M 0.01% 1333
2025
Q3
$61.6K Buy
+10,781
New +$57.5K ﹤0.01% 3276
2023
Q4
Sell
-121,047
Closed -$2.24M 2714
2023
Q3
$2.24M Buy
+121,047
New +$2.64M 0.02% 864
2023
Q2
Sell
-115,903
Closed -$2.15M 2773
2023
Q1
$2.15M Buy
+115,903
New +$2.18M 0.03% 746
2022
Q3
Sell
-56,827
Closed -$1.37M 2573
2022
Q2
$1.37M Buy
+56,827
New +$1.52M 0.04% 695
2022
Q1
Sell
-26,494
Closed -$1.2M 2446
2021
Q4
$1.2M Sell
26,494
-71,006
-73% -$3.04M 0.02% 904
2021
Q3
$4.23M Buy
97,500
+56,441
+137% +$2.46M 0.07% 329
2021
Q2
$1.89M Buy
+41,059
New +$1.9M 0.04% 588
2020
Q4
Sell
-39,256
Closed -$1.54M 1527
2020
Q3
$1.54M Buy
+39,256
New +$1.5M 0.07% 398
2014
Q3
Sell
-14,432
Closed -$219K 1451
2014
Q2
$219K Buy
+14,432
New +$214K 0.01% 996

Other funds holding NEOG

Tudor Investment Corp's NEOG Position: Q1 2026 in Review

Tudor Investment Corp reduced its Neogen (NEOG) stake by 56% in Q1 2026, selling an estimated $2.99M and leaving 235,741 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1779.

Tudor Investment Corp first reported a position in NEOG in Q2 2014 and has held it in 11 quarters since. The position peaked at $4.23M in Q3 2021. 307 funds tracked by Wall St. Rank hold NEOG as of Q1 2026.

  • Tudor Investment Corp held 235,741 shares of Neogen worth $2.19M as of Q1 2026.
  • Tudor Investment Corp sold 303,585 Neogen shares in Q1 2026, an estimated $2.99M.
  • Neogen made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #1779 holding.
  • Tudor Investment Corp first reported a position in Neogen in Q2 2014 and has held it in 11 quarters since.
  • Tudor Investment Corp's Neogen position peaked at $4.23M in Q3 2021.
  • 307 funds tracked by Wall St. Rank held Neogen as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.